Avacta Therapeutics appointed Francis Wilson as Chief Scientific Officer on February 9, 2026.23
Wilson joined Avacta in September 2022 as Vice President of Chemistry and contributed to the pre|CISION® platform, including IP for the sustained release mechanism in the AVA6103 program set for clinical trials soon.24
Previous roles include Research Scientist at Roche (1990-2001), Head of Chemistry at Xenova (2001-2003), Director of Chemistry at Cellzome (2003-2007), and Director of Chemistry at Summit Therapeutics (2007-2022).23
Wilson holds a chemistry degree and PhD from Oxford University, and is a Chartered Chemist and Fellow of the Royal Society of Chemistry.23
Former CSO Michelle Morrow is leaving to pursue another opportunity; CEO Christina Coughlin praised Wilson's expertise and leadership.24
Wilson expressed excitement about advancing AVA6103 to clinic and developing more IP for pre|CISION® platform.2
Sources:
2. https://www.biospace.com/press-releases/avacta-appoints-francis-wilson-as-chief-scientific-officer
3. https://www.marketscreener.com/news/avacta-therapeutics-announces-executive-changes-ce7e5adfdf8ff023
4. https://www.morningstar.com/news/alliance-news/1770632059862850700/avacta-appoints-new-chief-scientific-officer-plans-clinical-trials